A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.
Nb-UVB
1 other identifier
interventional
30
1 country
1
Brief Summary
A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jan 2025
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 23, 2025
CompletedFirst Submitted
Initial submission to the registry
September 8, 2025
CompletedFirst Posted
Study publicly available on registry
September 15, 2025
CompletedSeptember 15, 2025
September 1, 2025
4 months
September 8, 2025
September 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment.
Assess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment.
48 weeks
Study Arms (2)
patients will receive NB-UVB phototherapy sessions on a Randomly selected patch
ACTIVE COMPARATORpatients will receive NB-UVB phototherapy sessions on a Randomly selected patch
Patients will receive blue light emitting diodes phototherapy on a randomly selected patch
ACTIVE COMPARATORPatients will receive blue light emitting diodes phototherapy on a randomly selected patch
Interventions
type of phototherapy
type of diode
Eligibility Criteria
You may qualify if:
- All age group.
- Both genders.
- Subjects with stable non-segmental vitiligo (≥2 patches) acral or non-acral patches of diameter ≤ 2cm.
You may not qualify if:
- Prior treatment with laser therapies for at least 3 months
- Recent exfoliation procedures.
- Recent surgical procedures.
- Poor skin conditions including keloids.
- Hypersensitivity to light ( visible and near-infrared).
- Medications that make users more sensitive to light.
- Anticoagulant and immunosuppressive treatments.
- Gestations or breastfeeding.
- A personal or family history of skin cancer.
- Unstable vitiligo (older lesions have not progressed for the last 1 years and lack of Koebner phenomena ).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Cairo University
Giza, Cairo Governorate, 13114, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer of Dermatology
Study Record Dates
First Submitted
September 8, 2025
First Posted
September 15, 2025
Study Start
January 20, 2025
Primary Completion
May 20, 2025
Study Completion
August 23, 2025
Last Updated
September 15, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share